

CITATION REPORT

List of articles citing

Residual tumor cells that drive disease relapse after chemotherapy do not have enhanced tumor initiating capacity

DOI: 10.1371/journal.pone.0045647
PLoS ONE, 2012, 7, e45647.

Source: <https://exaly.com/paper-pdf/86985807/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
12	Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. <i>Science Translational Medicine</i> , 2013 , 5, 171ra18	17.5	59
11	Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 7-17	8.9	30
10	The sialyl-glycolipid stage-specific embryonic antigen 4 marks a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features. <i>Breast Cancer Research</i> , 2015 , 17, 146	8.3	35
9	Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 27313-26	6.3	34
8	Minimal residual disease in cancer therapy--Small things make all the difference. <i>Drug Resistance Updates</i> , 2015 , 21-22, 1-10	23.2	19
7	Development of nanotheranostics against metastatic breast cancer--A focus on the biology & mechanistic approaches. <i>Biotechnology Advances</i> , 2015 , 33, 1897-911	17.8	15
6	Prognostic significance of elevated serum CD44 levels in patients with oral squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2018 , 47, 665-673	3.3	10
5	mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. <i>Oncogene</i> , 2019 , 38, 622-636	9.2	27
4	Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549. <i>Neoplasia</i> , 2019 , 21, 185-196	6.4	27
3	Bromelain and Acetylcysteine (BromAc) alone and in combination with Gemcitabine inhibits subcutaneous deposits of pancreatic cancer after intraperitoneal injection.		
2	Emergent properties of a computational model of tumour growth. <i>PeerJ</i> , 2016 , 4, e2176	3.1	7
1	Bromelain and acetylcysteine (BromAc) alone and in combination with gemcitabine inhibit subcutaneous deposits of pancreatic cancer after intraperitoneal injection.. <i>American Journal of Translational Research (discontinued)</i> , 2021 , 13, 13524-13539	3	